10 reports of this reaction
2.0% of all FLUDEOXYGLUCOSE F 18 reports
#10 most reported adverse reaction
RASH MACULO PAPULAR is the #10 most commonly reported adverse reaction for FLUDEOXYGLUCOSE F 18, manufactured by Biomedical Research Foundation of Northwest Louisiana. There are 10 FDA adverse event reports linking FLUDEOXYGLUCOSE F 18 to RASH MACULO PAPULAR. This represents approximately 2.0% of all 510 adverse event reports for this drug.
Patients taking FLUDEOXYGLUCOSE F 18 who experience rash maculo papular should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RASH MACULO PAPULAR is a less commonly reported adverse event for FLUDEOXYGLUCOSE F 18, but still significant enough to appear in the safety profile.
In addition to rash maculo papular, the following adverse reactions have been reported for FLUDEOXYGLUCOSE F 18:
RASH MACULO PAPULAR has been reported as an adverse event in 10 FDA reports for FLUDEOXYGLUCOSE F 18. This does not prove causation, but indicates an association observed in post-market surveillance data.
RASH MACULO PAPULAR accounts for approximately 2.0% of all adverse event reports for FLUDEOXYGLUCOSE F 18, making it a notable side effect.
If you experience rash maculo papular while taking FLUDEOXYGLUCOSE F 18, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.